| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1a interim results example | Phase 1a | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1a interim results example | Phase 1a | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1a interim results example | Phase 1a | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Context Therapeutics Inc.$0.65
+0.06 (+10.85%)
D 33Pipeline Score Richly Valued Pharma · Clinical
Market Cap
238.89 M
EPS
-0.43
P/E Ratio
-
Value Trade
2.01 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
7.02 M
Operating CF
-11.43 M
Total Assets
58.86 M
Total Liabilities
6.66 M
Equity
52.20 M
D/E Ratio
12,345
13.54 %
Week
9.7 %
1 Month
12.07 %
3 Month
128.07 %
6 Month
-41.44 %
5 Year
-41.44 %
All Time
Cash Data
Cash Position
54.53 M
Monthly Burn
3.81 M
Runway
12.4 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
3.93 M
52 Week Range
0.49 - 3.62
% held by Insiders
9.93 %
% held by Institutions
57.42 %
Enterprise Value
184.64 M
Total Shares
91.83 M
Short %
4.76 %
Float Shares
67.49 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Context Therapeutics Inc.
223Total events
4Upcoming
47Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 4
Event history 219
Q3 2026
◆Trial InitiationCT-202Trial
Phase 1 clinical trial initiation for CT-202 expected in Q3 2026
solid tumorssource ↗
Q3 2026
▲First Patient DosedCT-202Trial
First patient dosed in CT-202 Phase 1 trial expected in Q3 2026
solid tumorssource ↗
Jun 15, 2026
▲Fast Track DesignationCTIM-76Designation
FDA Fast Track Designation granted for CTIM-76 in PROC
platinum-resistant ovarian cancersource ↗
Jun 15, 2026
▲Topline ReadoutCTIM-76Clinical Data
Positive interim efficacy and safety results from Phase 1a dose escalation
advanced solid tumors (PROC, testicular, endometrial)source ↗
Jun 15, 2026
●Oral PresentationCTIM-76Presentation
Investor conference call to discuss interim data
platinum-resistant ovarian cancersource ↗
Jun 3, 2026
Jun 2026
◆Interim AnalysisCTIM-76Trial
Interim data from Phase 1a trial expected
CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancerssource ↗
Jun 2026
◆Topline ReadoutCTIM-76Clinical Data
Phase 1a interim data for CTIM-76 expected in June 2026
CLDN6-positive solid tumorssource ↗
Jun 2026
◆Topline ReadoutCT-95Clinical Data
Initial Phase 1a data expected
pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancersource ↗
Jun 2026
Drug Pipeline Intelligence
D33
Pipeline Score $13M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 43%
Micro Cap (rank 520 of 911)
Percentile RankContext Therapeutics Inc. faces pipeline headwinds (33/100), with $103M risk-adjusted pipeline value, led by Onapristone in Granulosa Cell Ovarian Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onapristone Small molecule | Granulosa Cell Ovarian Cancer | Phase 2 | NCT03909152 | 19% | $39M | COMPLETED | 34 | - | - | Sep 3, 2024 | - | Jul 28, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CTIM-76 Fast Track | platinum-resistant ovarian cancer | Phase 1 | 2026-06-15 | overall response rate: 29%; disease control rate: 57%; CRS events: 11% Read More | Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 Read More | |
CTIM-76 Fast Track | platinum-resistant ovarian cancer | Phase 1 | 2026-06-15 | overall response rate: 29%; disease control rate: 57%; CRS events: 11% Read More | Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 Read More | |
CTIM-76 Fast Track | platinum-resistant ovarian cancer | Phase 1 | 2026-06-15 | overall response rate: 29%; disease control rate: 57%; CRS events: 11% Read More | Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CNTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CNTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CNTX▲ +9.8%on this news
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Context Therapeutics Inc. has been added to the Russell 2000 and Russell 3000 Indexes, effective June 26, 2026. This inclusion reflects the company's standing in the market as a clinical-stage biopharmaceutical firm focused on T cell engaging bispecific antibodies for solid tumors. The Russell Indexes serve as benchmarks for investment strategies and highlight the company's growth potential.
Read more →CNTX▼ -51.1%on this news
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
Context Therapeutics announced positive interim results from its Phase 1 trial of CTIM-76, a bispecific antibody for platinum-resistant ovarian cancer. The study showed a 29% overall response rate among patients, with a favorable safety profile. The drug has received FDA Fast Track Designation, and the company plans to explore a Q3W dosing schedule in future trials.
Read more →CNTX▼ -11.1%on this news
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Inc. announced the granting of a non-qualified stock option award for 146,000 shares to a new employee as per Nasdaq Listing Rule 5635(c)(4). The options, which have an exercise price of $1.71 per share, vest over four years with an emphasis on continued service. This initiative is part of Context's strategy to attract talent while advancing their portfolio of T cell engaging bispecific antibodies for solid tumors.
Read more →CNTX▲ +13.3%on this news
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
Context Therapeutics Inc. announced its upcoming presentation at the Jefferies Global Healthcare Conference on June 3, 2026. The company will showcase its advancements in T cell engaging bispecific antibodies for solid tumors. Additionally, Context granted stock options to a new employee, reflecting its growth strategy. However, the company acknowledges potential risks in its forward-looking statements.
Read more →CNTXForward-looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, inc
Context Therapeutics has amended its exclusive license agreement with BioAtla for CT-202, enabling it to obtain full economic rights. This move includes an upfront payment of $4.5 million, with an additional payment of $2 million due in August 2026. The company anticipates initiating a Phase 1 clinical trial for CT-202 in the third quarter of 2026. However, CT-202 is linked to potential adverse events and the company faces various operational risks moving forward.
Read more →CNTXContext Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context Therapeutics has amended its license agreement with BioAtla, allowing it to buy out future milestones and royalties for the CT-202 program. In return, Context will make a total payment of $6.5 million, thereby gaining full economic rights to CT-202, an antibody targeting Nectin-4, which is implicated in various solid tumors. The Phase 1 clinical trial of CT-202 is expected to commence in the third quarter of 2026, promising potential opportunities for long-term value as the company advances its development efforts. However, there are specific risks concerning the associated adverse events with Nectin-4 targeting.
Read more →CNTXContext Therapeutics Reports First Quarter 2026 Operating and Financial Results
Context Therapeutics has reported its financial results for the first quarter of 2026, highlighting a strong cash position of $54.5 million to fund operations into mid-2027. The company anticipates key clinical data from its ongoing studies, including CTIM-76 and CT-95, with updates expected later this year. Additionally, Context received FDA Fast Track Designation for CTIM-76, marking a significant milestone in treatment development for ovarian cancer. However, the company recorded a net loss of $8.7 million, which has increased compared to the same period last year, raising concerns about rising operational costs.
Read more →CNTXContext Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Context Therapeutics has announced that its bispecific antibody CTIM-76 has received Fast Track Designation from the FDA for the treatment of platinum-resistant ovarian cancer. This designation is designed to accelerate the development and review of therapies that meet serious unmet medical needs. Context is currently conducting a Phase 1 clinical trial to evaluate the safety and efficacy of CTIM-76, with interim data anticipated in June 2026. The designation highlights the potential of CTIM-76 to significantly impact patients who have exhausted standard treatment options.
Read more →CNTX▲ +5.3%on this news
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Context Therapeutics reported its financial results for 2025, highlighting significant advancements in its bispecific antibody pipeline. The company anticipates interim data for CTIM-76 in June 2026 and CT-95 in September 2026. With a cash balance of $66 million, Context expects to fund operations into mid-2027 and continue delivering clinical updates throughout 2026.
Read more →CNTXContext Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
Context Therapeutics Inc. announced it will be presenting a poster at the AACR Annual Meeting 2026, showcasing preclinical data for its bispecific antibody CT-202. This antibody targets Nectin-4, a protein associated with several solid tumors, and aims to enhance therapeutic efficacy in the tumor microenvironment. Scheduled for April 21, 2026, the presentation will contribute to the company's commitment to advancing novel cancer therapies. Potential risks related to CT-202 include adverse effects like neuropathy and rash.
Read more →CNTXContext Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Inc. has announced its participation in several upcoming investor conferences, showcasing its commitment to engaging with investors. The company is focused on developing T cell engaging bispecific antibodies for solid tumors. Live webcasts of the presentations will be accessible on their website, with replays available for 90 days.
Read more →CNTX▲ +6.9%on this news· ran to +26% by day 3
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
Context Therapeutics has announced the granting of non-qualified stock options to two new employees as an inducement for accepting employment. The awards, totaling 120,000 shares, were granted outside of the company's long-term incentive plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and vest over four years.
Read more →CNTX▼ -5.3%on this news· ran to +18% by day 3shared move
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Inc. announced the grant of non-qualified stock options to two newly hired employees as part of its inducement offers under Nasdaq Listing Rule 5635(c)(4). A total of 120,000 shares were awarded, with exercise prices set according to recent closing prices of the company's stock. The options come with a 10-year term and a four-year vesting schedule, reinforcing the company's aim to attract and retain talent in the competitive biopharmaceutical industry.
Read more →CNTXContext Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
Context Therapeutics showcased its CT-95 and CT-202 programs at the SITC 40th Annual Meeting. CT-95 targets mesothelin, while CT-202 focuses on Nectin-4, both aiming to enhance T cell engagement against solid tumors. The company plans to provide initial Phase 1a data for CT-95 by mid-2026 and initiate a first-in-human trial for CT-202 in Q2 2026.
Read more →CNTX▼ -5.3%on this newsshared move
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Context Therapeutics reported promising results from its ongoing Phase 1 trials for CTIM-76 and CT-95, indicating encouraging antitumor activity. The company holds $76.9 million in cash as of September 30, 2025, which is expected to fund operations into 2027. CEO Martin Lehr expressed optimism about the future of their T cell engaging bispecific antibodies.
Read more →CNTX▲ +10%on this news· ran to +27% by day 3
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Context Therapeutics Inc. has announced two poster presentations at the SITC 40th Annual Meeting, scheduled for November 7-9, 2025. The presentations will feature a Trial in Progress for the Phase 1 clinical trial of CT-95, a bispecific antibody targeting mesothelin, and preclinical data on CT-202, which targets Nectin-4. These developments highlight the company's commitment to advancing its T cell engaging bispecific antibodies for solid tumors.
Read more →CNTXContext Therapeutics Reports Second Quarter 2025 Operating and Financial Results
Context Therapeutics Inc. has reported its operating and financial results for the second quarter of 2025, showcasing ongoing Phase 1 studies for bispecific antibodies CTIM-76 and CT-95. The company confirmed it has sufficient cash reserves to fund operations into 2027 and expects to report initial dose escalation data from these trials in 2026. However, they also noted an increase in net losses and rising R&D expenses, primarily attributed to advancements in their development pipeline.
Read more →CNTXContext Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Context Therapeutics has announced a Trial in Progress poster presentation for its Phase 1 clinical trial of CTIM-76 at the 2025 ASCO Annual Meeting. The trial aims to evaluate the safety and efficacy of CTIM-76 in patients with CLDN6-positive advanced solid tumors. Initial data from the trial is expected to be shared in the first half of 2026.
Read more →CNTXContext Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
Context Therapeutics has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin, who has significant experience in T cell therapies, succeeds Dr. Karen Smith, who served as interim CMO. The company believes Dr. Chagin's expertise will be crucial in advancing their bispecific antibody portfolio for solid tumors.
Read more →CNTXContext Therapeutics Reports First Quarter 2025 Operating and Financial Results
Context Therapeutics Inc. reported its first quarter 2025 financial results, highlighting advancements in its clinical pipeline with two product candidates, CTIM-76 and CT-95, currently in Phase 1 trials. The company ended the quarter with $89.4 million in cash, expected to fund operations until 2027. However, Context experienced an increase in net loss for the quarter compared to the prior year. Upcoming presentations at industry conferences and the expected filing of an IND for CT-202 in 2026 indicate ongoing efforts to expand their innovative therapies for solid tumors.
Read more →CNTXContext Therapeutics Announces Chief Medical Officer Transition
Context Therapeutics has announced Dr. Karen Smith as the interim Chief Medical Officer, effective May 10, 2025. She is replacing Dr. Claudio Dansky Ullmann, who is departing the company. Dr. Smith, who has over 20 years of experience in biopharmaceutical development and currently serves on the Company’s Board of Directors, is expected to provide strategic guidance during the transition period. Context Therapeutics focuses on developing T cell engaging bispecific antibodies for solid tumors and is actively advancing its clinical pipeline.
Read more →CNTXContext Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
Context Therapeutics Inc. presented promising preclinical and translational data for CT-95, a bispecific T cell engager targeting mesothelin-expressing tumors, at the 2025 AACR Annual Meeting. The data suggest CT-95's effective binding to mesothelin, enabling targeted cancer treatment while minimizing issues associated with shed mesothelin. The company is currently conducting a Phase 1 clinical trial and has dosed its first patient, with initial clinical results expected in mid-2026. This development may address the unmet need for therapies in mesothelin-positive cancers such as pancreatic and ovarian cancers.
Read more →CNTXContext Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Context Therapeutics has successfully dosed the first patient in the Phase 1 clinical trial of CT-95, a bispecific antibody targeting mesothelin-expressing cancers. This milestone follows their earlier trial of CTIM-76 and highlights the company's commitment to developing immunotherapies for solid tumors. The Phase 1 trial will evaluate the safety and efficacy of CT-95 across various advanced solid tumors, with initial data expected to be shared in mid-2026. The trial aims to enroll up to 30 patients, focusing on assessing anti-tumor activity and safety.
Read more →CNTX▼ -8.6%on this news· ran to -29% by day 3
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Context Therapeutics Inc. announced a poster presentation for its clinical asset CT-95 at the AACR Annual Meeting 2025, scheduled for April 25-30 in Chicago. The poster will detail the determination of the first-in-human dose of CT-95, which targets mesothelin, a protein commonly overexpressed in various cancers. The dose is set at 0.1 µg/kg, based on the minimal anticipated biological effect level approach, suggesting it is positioned to achieve minimal biological effects in patients. This development indicates advancing research in T cell engaging bispecific antibodies for solid tumors.
Read more →CNTX▼ -6%on this news
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
Context Therapeutics Inc. announced its financial results for 2024, highlighting significant achievements in its clinical programs, including the first patient dosed in the Phase 1 trial of CTIM-76. The company reported a cash balance of $94.4 million, expected to support operations through 2027, alongside increasing R&D expenses primarily due to strategic acquisitions. Despite a net loss of $26.7 million, the firm remains focused on expanding its innovative T cell-engaging bispecific antibody portfolio for treating solid tumors.
Read more →CNTXContext Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Context Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial for CTIM-76, a bispecific antibody targeting CLDN6, focused on treating CLDN6-positive gynecologic and testicular cancers. The trial aims to assess safety, tolerability, and anti-tumor activity with an expected enrollment of up to 70 patients. Initial data is anticipated in the first half of 2026, marking a significant step in the company’s drug development pipeline.
Read more →CNTXContext Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Context Therapeutics has appointed Andy Pasternak as Chairman of the Board of Directors, succeeding Richard Berman. This transition is expected to leverage Pasternak's extensive experience in the biopharmaceutical sector to guide the company through its next growth phase. Pasternak is noted for his role in the $28 billion acquisition of Horizon Therapeutics by Amgen and has served on various boards within the industry. Context is focused on advancing T cell engagers for solid tumors and aims to leverage Pasternak's leadership for future advancements.
Read more →CNTXImportant Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company's current views about future events a
Context Therapeutics Inc. presented an overview of its advances in T cell engager (TCE) therapies aimed at treating solid tumors. Their pipeline includes several promising candidates that have demonstrated efficacy and safety in preliminary trials. The company maintains a robust financial position, with a recent equity investment and expected runway into 2027. However, the presentation also highlights inherent risks and uncertainties associated with forward-looking statements, including safety and efficacy of their product candidates.
Read more →CNTXContext Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Context Therapeutics Inc. reported its third quarter 2024 financial results, highlighting the expansion of its pipeline with two new T cell engaging bispecific antibodies. The company finished the quarter with $84.8 million in cash and has plans to initiate Phase 1 trials for its new drugs, CT-95 and CT-202, with patient dosing expected soon. Despite the positive developments, Context's net loss for the quarter increased significantly compared to last year, indicating ongoing financial challenges.
Read more →CNTX▲ +11.5%on this news
Context Therapeutics to Participate in Upcoming Investor Conferences in November
Context Therapeutics Inc. announced its participation in several upcoming investor conferences in November, including the Guggenheim, UBS, and Stifel healthcare conferences. The company plans to engage in fireside chats and presentations, as well as one-on-one meetings to discuss its advancements in T cell engagers for solid tumors. Live webcasts of these events will be available for stakeholders, aiming to enhance communication with the investment community. However, the statement emphasizes the presence of risks and uncertainties associated with the company's forward-looking statements.
Read more →CNTX▲ +5.1%on this news
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Context Therapeutics Inc. announced that it will present a poster on its clinical asset, CTIM-76, at the Society for Immunotherapy of Cancer's 39th Annual Meeting. The poster will detail the determination of the first-in-human dose of this bispecific antibody targeting Claudin 6, effective for various solid tumors. The conference is set to take place from November 8-10, 2024, in Houston, TX. Context is focusing on innovative T cell engaging therapeutics to enhance cancer treatment.
Read more →CNTXContext Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
Context Therapeutics announced the appointment of Dr. Karen Smith and Dr. Luke Walker to its Board of Directors, enhancing its leadership as the company focuses on advancing its oncology pipeline. Dr. Smith brings over 20 years of experience in oncology drug development, while Dr. Walker has led clinical development efforts in significant oncology projects. Both appointees are expected to contribute to Context's goal of becoming a leading oncology company through innovative bispecific therapeutics. CEO Martin Lehr emphasized that their expertise will support the company's growth trajectory.
Read more →CNTXContext Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Context Therapeutics Inc. has announced its financial results for the second quarter of 2024, reporting a net loss of $2.3 million. The company highlighted their acquisition of CT-95, a mesothelin x CD3 bispecific antibody, and the initiation of a Phase 1 trial for CTIM-76, a Claudin 6 x CD3 bispecific antibody, expected in the third quarter. Additionally, the appointment of Dr. Claudio Dansky Ullmann as Chief Medical Officer aims to strengthen the company's leadership in oncology. Context's cash and cash equivalents stood at $101.5 million, projected to sufficiently fund upcoming trials into 2028.
Read more →CNTXContext Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Context Therapeutics Inc. has appointed Dr. Claudio Dansky Ullmann as Chief Medical Officer and Ms. Karen Andreas as Vice President of Clinical Operations. These appointments aim to support the development of the company's clinical-stage T cell engaging assets for solid tumors, namely CTIM-76 and CT-95, which are entering Phase 1 clinical trials. Both new leaders bring extensive experience in oncology, enhancing the company’s operational capabilities. Additionally, compensation in the form of stock options has been announced for both hires, aligning their interests with company performance.
Read more →CNTXContext Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Context Therapeutics has acquired CT-95, a mesothelin x CD3 bispecific antibody, from Link Immunotherapeutics, aiming for Phase 1 trials in early 2025. The acquisition enhances Context's pipeline, with CT-95 expected to address solid tumors, notably in ovarian, lung, and pancreatic cancers. The company plans to fund ongoing trials with its existing cash. CEO Martin Lehr emphasizes CT-95's potential as a first-in-class therapy, supported by positive preclinical data.
Read more →CNTX▲ +5.2%on this news
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
Context Therapeutics reported significant achievements in the first quarter of 2024, including FDA clearance for its CTIM-76 IND application, which allows for the start of a Phase 1 clinical trial in patients with specific cancers. The company also secured $100 million through a private placement, expected to fund operations into 2028. While cash and equivalents have decreased, the overall company outlook remains optimistic due to regulatory advancements and upcoming clinical milestones.
Read more →CNTX▲ +28.7%on this news
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
Context Therapeutics Inc. has received FDA clearance for its IND application for CTIM-76, a bispecific antibody targeting CLDN6, indicating a significant step forward for its clinical trials. The Phase 1 trial will focus on patients with CLDN6-positive gynecologic and testicular cancers, with expectations to enroll the first patient by mid-2024. The company aims to assess safety, tolerability, pharmacokinetics, and anti-tumor activity in this study. This development positions Context Therapeutics to potentially introduce a promising new treatment option within the oncology market.
Read more →CNTX▲ +28.7%on this news
Context Therapeutics Announces $100 Million Private Placement
Context Therapeutics has announced a substantial private placement expected to raise approximately $100 million from new and existing investors. This funding is vital for extending the company’s cash runway through 2028 and supports the ongoing development of the CTIM-76 Phase 1 clinical trial. The private placement will close on May 6, 2024, pending customary closing conditions. The company is also emphasizing its commitment to future regulatory approvals and product development despite inherent risks.
Read more →CNTXContext Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Context Therapeutics has submitted an Investigational New Drug (IND) application to the FDA for CTIM-76, aimed at treating Claudin 6-positive cancers. The application supports a Phase 1 clinical trial for CTIM-76, which is a bispecific antibody intended to target various solid tumors. The IND submission is seen as a significant achievement by the company, bolstered by extensive preclinical and manufacturing data. The trial aims to explore CTIM-76's efficacy while highlighting its favorable safety profile and dosing convenience.
Read more →CNTX▼ -7%on this news
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Context Therapeutics Inc. announced its financial results for the year ending December 31, 2023, highlighting the progress of its lead candidate CTIM-76 towards clinical trials. The company expects to file for an Investigational New Drug Application by the end of March 2024 and initiate a Phase 1 trial for gynecologic and testicular cancers. Financially, Context reported a net loss of $24 million, with cash reserves projected to support operations into late 2024. While the decrease in cash reserves raises concerns, impressive preclinical data for CTIM-76 positions the company favorably in its field.
Read more →CNTXContext Therapeutics Reports Third Quarter 2023 Operating and Financial Results
Context Therapeutics Inc. has announced its third quarter 2023 operating and financial results, highlighting significant advancements in its lead clinical candidate CTIM-76. The company expects to file an Investigational New Drug application with the FDA by late Q1 2024, following promising preclinical data demonstrating the candidate's effectiveness against CLDN6-positive tumors. Financially, while cash reserves are expected to sustain operations into late 2024, the company reported a net loss of $5.9 million, an increase from the previous year, attributed to higher research and development costs.
Read more →CNTXContext Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
Context Therapeutics announced encouraging preclinical data for its bispecific antibody CTIM-76, targeting Claudin 6-positive tumors. The data highlights the drug's high potency and ability to induce tumor regressions, with favorable safety profiles in preclinical models. An Investigational New Drug (IND) filing is on track for late Q1 2024, with additional data to be presented at the upcoming SITC meeting. This product could address a significant unmet need, as there are no approved treatments for this patient population in the U.S.
Read more →CNTX▲ +16.2%on this news· ran to +27% by day 3
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Context Therapeutics has announced that an abstract detailing its preclinical asset CTIM-76 will be presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The event is scheduled to take place from November 3-5, 2023, in San Diego, CA. CTIM-76 is a Claudin 6 x CD3 bispecific antibody aimed at treating CLDN6-positive tumors. The presentation signifies recognition of the company's innovative approach to solid tumors and highlights the ongoing efforts in the biopharmaceutical sector.
Read more →CNTX▼ -9.6%on this news
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Context Therapeutics Inc. reported its financial results for the second quarter of 2023, revealing a net loss of $5.0 million. As of June 30, 2023, the company had cash and cash equivalents of $25.1 million, expected to last into late 2024. The company is progressing with its preclinical asset CTIM-76, which targets CLDN6-positive tumors, and plans to file an IND application in the first quarter of 2024. Context also announced participation in upcoming biotechnology conferences to discuss its developments.
Read more →CNTX▲ +7.3%on this news
Context Therapeutics to Participate in Two August 2023 Investor Conferences
Context Therapeutics Inc. announced that its CEO, Martin Lehr, will participate virtually in two investor conferences in August 2023. The first conference is the BTIG Virtual Biotechnology Conference on August 7, followed by the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17. The company focuses on developing CTIM-76, a bispecific antibody aimed at treating CLDN6-positive tumors. Context aims to improve the lives of patients with cancer while actively engaging with investors.
Read more →CNTXContext Therapeutics Reports First Quarter 2023 Operating and Financial Results
Context Therapeutics Inc. reported its financial results for the first quarter of 2023, detailing a net loss of $6.3 million, up from $3.4 million in the same period last year. The company is focusing its portfolio on the preclinical asset CTIM-76, a bispecific antibody targeting CLDN6-positive tumors, with an IND filing expected in Q1 2024. Their cash reserves as of March 31, 2023, stood at $29.8 million, which is projected to fund operations into late 2024, despite a decrease from the previous quarter. Recent preclinical results presented highlight the potential of CTIM-76 in cancer immunotherapy.
Read more →CNTX▲ +5.9%on this news
Context Therapeutics to Participate in Two April 2023 Investor Conferences
Context Therapeutics Inc. has announced that CEO Martin Lehr will participate virtually in two upcoming investor conferences in April 2023. The events include the Diamond Equity Emerging Growth Invitational on April 5 and the 22nd Annual Needham Virtual Healthcare Conference on April 19, where the company will also engage in one-on-one meetings. The company's focus remains on the development of CTIM-76, a bispecific antibody for CLDN6-positive tumors, currently in preclinical development.
Read more →CNTXContext Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
Context Therapeutics Inc. reported its financial results for the year ended December 31, 2022, and updated its pipeline strategy. The company will discontinue the development of ONA-XR while focusing on CTIM-76, a bispecific antibody targeting CLDN6-positive tumors, with expected preclinical data presentation at the AACR Annual Meeting 2023. Despite a reported net loss of $14.8 million, Context has extended its cash runway into late 2024, ensuring funding for the further development of CTIM-76 through its anticipated IND application in early 2024.
Read more →CNTXContext Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Context Therapeutics has announced that its abstract regarding the preclinical candidate CTIM-76 has been accepted for presentation at the AACR Annual Meeting 2023. The presentation will detail the development of CTIM-76, a bispecific antibody targeting Claudin 6 for ovarian cancer treatment. This presentation is scheduled for April 17, 2023. Following the session, Context will conduct a webinar to discuss results and provide updates on the CTIM-76 program.
Read more →CNTX▲ +5.3%on this news
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
Context Therapeutics has reported initial positive results from the Phase 2 OATH clinical trial evaluating its treatment ONA-XR for metastatic endometrial cancer. Among the first 12 patients, two achieved a confirmed partial response, indicating promising therapeutic potential. The combination of ONA-XR with anastrozole showed a 4-month progression-free survival rate of 77%, suggesting better efficacy and tolerability than standard treatment options. Additional data updates are expected in Q2 2023.
Read more →CNTX▲ +55.2%on this news
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
Context Therapeutics announced that its clinical partner, Stemline Therapeutics, received FDA approval for ORSERDU (elacestrant) to treat ER+, HER2-, ESR1-mutated breast cancer. This marks a significant advancement in the treatment of advanced breast cancer, showing improved efficacy over current therapies. ORSERDU is also being evaluated in combination with Context's ONA-XR in the ongoing ELONA trial, which aims to explore enhanced treatment potential. This development could shift the treatment paradigm for patients with ESR1 mutations, which represent a considerable subset of advanced breast cancer cases.
Read more →CNTX▲ +8.3%on this news
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Context Therapeutics has entered into a manufacturing agreement with Lonza to develop and manufacture their bispecific antibody candidate, CTIM-76, targeting Claudin 6-positive cancers. The collaboration aims to leverage Lonza's expertise in the manufacturing of complex proteins, which is vital for the clinical development of CTIM-76. The drug is currently in preclinical development and is designed to enhance T-cell-mediated lysis of cancer cells while minimizing systemic immunotoxicity. This agreement signals a strategic effort by Context to improve the scalability of their therapeutic candidates.
Read more →CNTX▲ +9.8%on this news· ran to +25% by day 3shared move
Context Therapeutics Highlights 2023 Corporate Priorities and Pipeline Milestones
Context Therapeutics Inc. has outlined its corporate priorities and clinical milestones for 2023, highlighting significant advancements in its pipeline. The company has nominated CTIM-76 as a clinical candidate for a Claudin 6 bispecific antibody and is reporting positive preliminary data from ongoing ONA-XR trials for endometrial and breast cancer. Additionally, Context has successfully enrolled its first patient in the ELONA trial, which aims to explore the efficacy of ONA-XR in combination with Menarini's elacestrant. The company’s financial position is expected to support operations into early 2024 as it works toward regulatory submissions and further clinical trials.
Read more →CNTX▼ -28.4%on this news· ran to -44% by day 3
Context Therapeutics Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows recently disclosed positive preliminary data in ongoing Phase 2 endometrial cancer trial
Read more →CNTXContext Therapeutics Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December 1, 2022, at 11 a.m. ET PHILADELPHIA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (
Read more →CNTXContext Therapeutics Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
PHILADELPHIA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today announced clinical data on onapristone extended release (ONA-XR)
Read more →CNTXContext Therapeutics Reports Third Quarter 2022 Operating and Financial Results
Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR+ recurrent endometrial cancer ONA-XR continues
Read more →CNTXContext Therapeutics Amends Cash Guidance, Extends Runway into Q1 2024
PHILADELPHIA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecological cancers, today announced updated cash guidance to extend its runway into Q1
Read more →CNTXContext Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will parti
Read more →CNTX▲ +9.7%on this news
Context Therapeutics Reports Second Quarter 2022 Operating and Financial Results
Announced new clinical trial collaboration with Menarini Group to evaluate ONA-XR plus elacestrant in metastatic breast cancer Results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary presented at the 2022 ASCO Annual Meeting Pre
Read more →CNTX▲ +5.8%on this news
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Conte
Read more →CNTX▼ -5.1%on this news
Context Therapeutics Reports First Quarter 2022 Operating and Financial Results
Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data presented at AACR Annual Meeting showcased potential of ONA-XR and CLDN6xCD3 bisp
Read more →CNTXContext Therapeutics Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary Trial advanced to second stage to evaluate combination of ONA-XR with oral antiestrogen PHILADELPHIA, May 05, 2022 (GLO
Read more →CNTX▼ -22.2%on this news
Context Therapeutics Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First presentation of preclinical CLDN6xCD3 bispecific antibody optimization, binding properties, and T-cell dependent cytotoxicity Context
Read more →CNTXContext Therapeutics to Participate in Two April 2022 Investor Conferences
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Off
Read more →CNTXContext Therapeutics Reports Full Year 2021 Operating and Financial Results
Investor R&D event on April 13th to highlight new preclinical data to be presented at AACR Annual Meeting Strong cash position following $28.75M initial public offering and $31.25M private placement PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Co
Read more →CNTXContext Therapeutics Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have
Read more →CNTXContext Therapeutics to Participate in the Sachs 15th Annual European Life Sciences CEO Forum
PHILADELPHIA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Offi
Read more →CNTX▼ -9.1%on this news
Context Therapeutics Strengthens Research & Development Team
PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced the appointments of Chris
Read more →CNTXContext Therapeutics to Participate in Two January 2022 Investor Conferences
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Offi
Read more →CNTX▲ +24.2%on this news
Context Therapeutics Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium
Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented PHILADELPHIA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX
Read more →CNTXContext Therapeutics Inc. Announces Closing of $31.25 Million Private Placement
PHILADELPHIA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today anno
Read more →CNTX▼ -20%on this newsshared move
Context Therapeutics Reports Third Quarter 2021 Operating and Financial Results
Entered into $31.25 million Private Placement Agreement Completed Initial Public Offering of Common Stock and Raised $28.75 million in Gross Proceeds Dosed First Patient in Phase 2 ER+, PR+, HER2- Metastatic Breast Cancer Clinical Trial PHILADELPHIA, Dec. 02, 2021 (GLOBE NEWSW
Read more →CNTXContext Therapeutics Inc. Announces $31.25 Million Private Placement
PHILADELPHIA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today anno
Read more →CNTX▲ +9.9%on this news
Context Therapeutics to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium
PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announced clinical data on onapristone extende
Read more →CNTXContext Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer
PHILADELPHIA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, today announced the appointm
Read more →CNTX▼ -7.3%on this news· ran to -23% by day 3shared move
Context Therapeutics and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer
PHILADELPHIA, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Wisconsin Oncology Netwo
Read more →CNTX▲ +13.3%on this newsshared move
Context Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment Option
PHILADELPHIA, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, today announ
Read more →CNTXContext Therapeutics Announces Pricing of Initial Public Offering
PHILADELPHIA, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, today announ
Read more →CNTXContext Therapeutics and Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone
PHILADELPHIA and SHANGHAI, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”), a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Tyl
Read more →CNTXContext Therapeutics and Jefferson Health Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Advanced Endometrial Cancer
PHILADELPHIA, May 12, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics, a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and the Sidney Kimmel Cancer Center – Jefferson H
Read more →CNTXContext Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program
PHILADELPHIA, April 08, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Integral Molecular, the lead
Read more →CNTXContext Therapeutics Expands Board of Directors
-- Company Adds Richard Berman, Jennifer Evans Stacey and Linda West to Board -- -- Appointments Bolster Business and Clinical Development and Commercial Strategy Expertise as Context Prepares to Advance ONA-XR into Late-Stage Trials -- PHILADELPHIA, March 22, 2021 (GLOBE NEWSW
Read more →CNTXContext Matters Introduces Solid Tumor Cancer Module Into Its Proprietary Reimbursement Risk Tracker(TM) at American Society of Clinical Oncology (ASCO) Conference
NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- Context Matters announces the addition of a solid tumor cancer module into its proprietary thin-client, cloud-based web application and data platform, the Reimbursement Risk Tracker (RRT), which provides pharmaceutical and biotechnology
Read more →Competitive Position
How CNTX ranks across every disease it competes inCompetitive Position is a premium feature
See how CNTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial